Shots:

• Generium’s biosimilar of Eculizumab is developed using Selexis’ SUREtechnology Platform which is based on Selexis SGE (Selexis Genetic Elements) consist of human DNA based element- controlling the chromatin across mammalian cells
• Eculizumab is a monoclonal IgG2/4 Ab developed as a fifth biosimilar SUREtechnology Platform involved in reduction of the destruction of red blood cells and need for blood transfusion & improves renal function in patients with PNH & aHUS respectively
• Currently 115 clinical programs are utilizing the SUREtechnology Platform including 9 P-III programs useful in addressing complicated and intractable diseases by developing complex protein therapies

Ref: Selexis | Image: Twitter